---
document_datetime: 2025-10-29 12:23:30
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/rybrevant-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: rybrevant-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.1935533
conversion_datetime: 2025-12-28 12:22:03.257392
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Rybrevant

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a group of | 13/10/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000287530                     | variations. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.z Other variation - Accepted   |            |     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000287115 | This was an application for a group of variations. B.II.d.2 Change in test procedure for the finished product - B.II.d.2.d Other changes to a test procedure (including replacement or addition) - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.f Deletion of a specification parameter which may have a significant effect on the overall quality of the                                                                                               | 02/10/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | finished product - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000261993 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.2, 4.4 and 4.8 of the SmPC for Rybrevant and Lazcluze in order to include updated information on enhanced dermatologic management regimen as prophylactic treatment to reduce the risk of dermatological toxicities during treatment, based on results from study 61186372NSC2007. Study 61186372NSC2007 (COCOON) is a Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR- mutated NSCLC treated first-line with amivantamab + lazertinib. The Package | 18/09/2025 | SmPC and PL | SmPC new text Based on the results of a phase 2 study in patients treated with amivantamab in combination with lazertinib assessing the use of prophylactic therapy with an oral antibiotic, a topical antibiotic on the scalp, a moisturiser on the face and whole body and an antiseptic on hands and feet, recommendations on dermatologic management have been strenghten in sections 4.2 and 4.4 of the SmPC of both products. Prophylactic therapy with oral and topical antibiotics is recommended to reduce the risk and severity of skin and nail reactions in patients receiving amivantamab and lazertinib at treatment initiation. Non comedogenic skin moisturiser (ceramide based or other formulations that provide long lasting skin hydration and exclude drying agents are preferred) on the face and whole body (except scalp) and chlorhexidine solution to wash hands and feet are also recommended beginning on day1 and continued foe the duration of treatment. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                                       | the MAH took the opportunity to introduce minor corrections to the PI for Lazcluze and Rybrevant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |             |           |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------|
| Variation type IB / EMA/VR/0000278107 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes | 04/09/2025 | N/A        |             |           |
| PSUR / EMA/PSUR/0000248975            | - - In view of available data on skin ulcer from clinical trials, the literature, spontaneous reports and in view of a plausible mechanism of action, the PRAC considers a causal relationship between amivantamab and skin ulcer is at least a reasonable possibility. The PRAC concluded that the product information                                                                                                                                                                                                                                                                                                                      | 19/06/2025 | 21/08/2025 | SmPC and PL | Variation |

<div style=\"page-break-after: always\"></div>

|                                       | of products containing amivantamab should be amended accordingly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000253354 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 5.1 of the SmPC in order to provide final Overall Survival (OS) data following Rybrevant extension of indication procedure (EMEA/H/C/005454/II/0013), and Lazcluze MAA approval (EMEA/H/C/006074/0000), and based on final results from study 73841937NSC3003 (MARIPOSA); this is a pivotal randomized, open-label, Phase 3 study that compares the efficacy and safety of the combination of amivantamab and lazertinib (Arm A) versus osimertinib monotherapy (Arm B) and lazertinib monotherapy (Arm C) in | 19/06/2025 | SmPC | SmPC new text OS, intracranial ORR and DOR data were updated in section 5.1 of the SmPC based on final results from the Mariposa study (a pivotal randomized, open-label, Phase 3 study that compares the efficacy and safety of the combination of amivantamab and lazertinib (Arm A) versus osimertinib monotherapy (Arm B) and lazertinib monotherapy (Arm C) in participants with EGFRm NSCLC): The final analysis of OS demonstrated a statistically significant improvement in OS for Rybrevant in combination with lazertinib compared to Osimertinib and the intracranial ORR and DOR were updated. For more information, please refer to the Summary of Product Characteristics. |
| Variation type IB / EMA/VR/0000272581 | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 18/06/2025 | SmPC |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                                       | the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000257307 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.2 and 4.8 of the SmPC in order to change posology recommendations for the premedication regimen to include a higher and extended dose regimen of oral dexamethasone, in addition to the currently approved labelled 20 mg to reduce the incidence and severity of amivantamab-related infusion related reactions (IRRs), based on results from the SKIPPirr study (61186372NSC2005). This is a Phase 2, proof-of-concept, open label, multicentre study conducted in participants with EGFR exon 19deletion or L858R mutated NSCLC who have progressed on or after prior osimertinib and on or after platinum chemotherapy. This study aimed to assess the use of 4 independent pretreatment medication regimens for the prophylaxis of amivantamab-related IRRs. In | 22/05/2025 | 30/07/2025 | SmPC and PL | SmPC new text Based on the results of a phase 2 open-label multicenter study in patients with NSCLC, premedication strategy for Rybrevant has been revised in section 4.2 of the SmPC as follows: During the two days prior to the initial Rybrevant infusion, patients should receive 8 mg dexamethasone orally, twice daily. On the day of the initial infusion (Week 1, Day 1), patients should receive 8 mg dexamethasone orally, one hour prior to infusion in addition to intravenous dexamethasone to further reduce the risk of IRRs. Section 4.8 of the SmPC has also been revised in order to state that with the addition of oral dexamethasone, a 22.5% incidence of IRRs and no grade â‰¥3 IRRs were reported on the day of the initial infusion. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                                       | update the list of local representatives in the Package Leaflet.                                                                                                         |            |     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000265968 | B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.b Addition of a new in- process test and limits - Accepted | 15/05/2025 | N/A |